1. KCBD11 . Live coronavirus COVID-19 global cases map. Available from: https://www.kcbd.com/2020/03/16/live-coronavirus-covid-global-cases-map/. Accessed March 5, 2021.
Google Scholar2. amfAR . Available from: https://www.amfar.org/about-hiv-and-aids/facts-and-stats/statistics--worldwide/. Accessed March 5, 2021.
Google Scholar3. Belot, M, Choi, S, Tripodi, E, Broek-Altenburg, Evd, Jamison, JC, Papageorge, NW. Unequal consequences of Covid 19: representative evidence from six countries. Rev Econ Househ. 2021:1–15.
Google Scholar4. Crossley, TF, Fisher, P, Low, H. The heterogeneous and regressive consequences of COVID-19: evidence from high quality panel data. J Public Econ. 2021;193:104334.
Google Scholar | Crossref | Medline5. Garre-Olmo, J, Turró-Garriga, O, Martí-Lluch, R, et al. Changes in lifestyle resulting from confinement due to COVID-19 and depressive symptomatology: a cross-sectional a population-based study. Compr Psychiatry. 2021;104:152214.
Google Scholar | Crossref | Medline6. Fitzpatrick, MC, Singer, BH, Hotez, PJ, Galvani, AP. Saving lives efficiently across sectors: the need for a congressional cost-effectiveness committee. Lancet. 2017;390(10110):2410–2.
Google Scholar | Crossref | Medline7. Galárraga, O, Colchero, MA, Wamai, RG, Bertozzi, SM. HIV prevention cost-effectiveness: a systematic review. BMC Public Health. 2009;9(suppl 1):S5.
Google Scholar | Crossref | Medline8. Canning, D . The economics of HIV/AIDS in low-income countries: the case for prevention. J Econ Perspect. 2006;20(3):121–42.
Google Scholar | Crossref | Medline9. Cohen, D, Shin-Yi, W, Farley, T. Cost-effective allocation of government funds to prevent HIV infection. Health Aff (Millwood). 2005;24(4):915–26.
Google Scholar | Crossref | Medline10. Walker, D . Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan. 2003;18(1):4–17.
Google Scholar | Crossref | Medline11. Creese, A, Floyd, K, Alban, A, Guinness, L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635–42.
Google Scholar | Crossref | Medline | ISI12. Paltiel, AD, Stinnett, AA. Handbook of Economic Evaluation of HIV Prevention Programs: New York: Springer; 1998.
Google Scholar | Crossref13. Coates, TJ, Richter, L, Caceres, C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372(9639):669–84.
Google Scholar | Crossref | Medline | ISI14. HIV Modelling Consortium Treatment as Prevention Editorial Writing Group . HIV treatment as prevention: models, data, and questions—towards evidence-based decision-making. PLoS Med. 2012;9(7):e1001259.
Google Scholar15. Hogan, DR, Baltussen, R, Hayashi, C, Lauer, JA, Salomon, JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331(7530):1431.
Google Scholar | Crossref | Medline16. Alistar, SS, Brandeau, ML. Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice. Med Decis Making. 2012;32(1):105–17.
Google Scholar | SAGE Journals | ISI17. Boily, M-C, Mâsse, B, Alsallaq, R, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med. 2012;9(7):e1001250.
Google Scholar | Crossref | Medline | ISI18. Hecht, R, Stover, J, Bollinger, L, Muhib, F, Case, K, de Ferranti, D. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009–31. Lancet. 2010;376(9748):1254–60.
Google Scholar | Crossref | Medline19. Izazola-Licea, JA, Wiegelmann, J, Arán, C, Guthrie, T, De Lay, P, Avila-Figueroa, C. Financing the response to HIV in low-income and middle-income countries. J Acquir Immune Defic Syndr. 2009;52:S119–26.
Google Scholar | Crossref | Medline20. Goldie, SJ, Yazdanpanah, Y, Losina, E, et al. Cost-effectiveness of HIV treatment in resource-poor settings—the case of Côte d’Ivoire. N Engl J Med. 2006;355(11):1141–53.
Google Scholar | Crossref | Medline21. Moxnes, JF, Hausken, K. Mathematical modelling of acute virus influenza A infections. Math Comput Model Dyn Syst. 2012;18(5):521–38.
Google Scholar | Crossref22. Bertozzi, S, Padian, NS, Wegbreit, J, et al. HIV/AIDS prevention and treatment. Dis Control Prior Dev Countries. 2006;2:331–70.
Google Scholar23. Gonsalves, G . HIV/AIDS prevention and treatment. Lancet. 2002;360(9326):87.
Google Scholar | Crossref | Medline24. Kumaranayake, L, Watts, C, Dixon, S, McDonald, S, Roberts, J. Resource allocation and priority setting of HIV/AIDS interventions: addressing the generalized epidemic in Sub-Saharan Africa. J Int Dev. 2001;13(4):451–66.
Google Scholar | Crossref25. Granich, R, Kahn, JG, Bennett, R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050 (expanding ART for HIV treatment and prevention). PLoS One. 2012;7(2):e30216.
Google Scholar | Crossref | Medline | ISI26. Bärnighausen, T, Salomon, JA, Sangrujee, N. HIV Treatment as prevention: issues in economic evaluation. PLoS Med. 2012;9(7):1001263.
Google Scholar | Crossref27. Forsythe, SS, McGreevey, W, Whiteside, A, et al. Twenty years of antiretroviral therapy for people living with HIV: global costs, health achievements, economic benefits. Health Aff (Millwood). 2019;38(7):1163–72.
Google Scholar | Crossref | Medline28. DiMasi, JA, Grabowski, HG, Hansen, RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
Google Scholar | Crossref | Medline | ISI29. West, DM, Schneider, J. Measuring revenue streams and profitability for HIV drugs . 2018. Available from:https://www.brookings.edu/research/measuring-revenue-streams-and-profitability-for-hiv-drugs/
Google Scholar30. Kremer, M, Snyder, CM. Why Are Drugs More Profitable Than Vaccines?Cambridge (MA): National Bureau of Economic Research; 2003.
Google Scholar | Crossref31. Kremer, M, Snyder, CM. Preventatives versus Treatments. Cambridge (MA): Department of Economics, Harvard University;2015.
Google Scholar32. Thomas, P . Big Shot: Passion, Politics, and the Struggle for an AIDS Vaccine. New York: Public Affairs; 2001.
Google Scholar33. Kremer, M, Glennerster, R. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton (NJ): Princeton University Press; 2004.
Google Scholar34. Hausken, K, Ncube, M. Game theoretic analysis of persons, the pharmaceutical industry, and donors in disease contraction and recovery. Humanities & Social Sciences Communications. 2020;7(150):1–17.
Google Scholar35. Mamani, H, Chick, SE, Simchi-Levi, D. A game-theoretic model of international influenza vaccination coordination. Manage Sci. 2013;59(7):1650–70.
Google Scholar | Crossref36. Hausken, K, Ncube, M. Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS. Health Econ Rev. 2017;7(1):1–12.
Google Scholar | Crossref | Medline37. Hausken, K, Ncube, M. Policy makers, the international community and people living with HIV/AIDS: the need for new commitment mechanisms. International Journal of Public Policy. 2018;14(3/4):275–301.
Google Scholar | Crossref38. Cornish, L . Interactive: who’s funding the Covid-19 response and what are the priorities?2021. Available from: https://www.devex.com/news/interactive-who-s-funding-the-covid-19-response-and-what-are-the-priorities-96833
Google Scholar39. Cao, S . COVID-19 vaccine prices revealed from Pfizer, Moderna, and AstraZeneca. The Observer. November 23, 2020. Available from: https://observer.com/2020/11/covid19-vaccine-price-pfizer-moderna-astrazeneca-oxford/. Accessed March 5, 2021.
Google Scholar40. Sguazzin, A . Pfizer has offered South Africa discounted Covid-19 vaccines. Bloomberg. January 4, 2021. Available from: https://www.bloomberg.com/news/articles/2021-01-04/pfizer-has-offered-south-africa-discounted-covid-19-vaccines. Accessed March 5, 2021.
Google Scholar41. Lansdowne LE . Exploring the drug development process. 2020. Available from: https://www.technologynetworks.com/drug-discovery/articles/exploring-the-drug-development-process-331894
Google Scholar42. Drugs.com . Hydroxychloroquine prices, coupons and patient assistance programs. Available from: https://www.drugs.com/price-guide/hydroxychloroquine. Accessed March 5, 2021.
Google Scholar43. Drugs.com . Hydroxychloroquine (oral). Available from: https://www.drugs.com/cons/hydroxychloroquine.html. Accessed March 5, 2021.
Google Scholar44. Drugs.com . Ivermectin prices, coupons and patient assistance programs. Available from: https://www.drugs.com/price-guide/ivermectin. Accessed March 5, 2021.
Google Scholar45. Michael, E . ‘This was a gift to us’: ivermectin effective for COVID-19 prophylaxis, treatment. Healio. Available from: https://www.healio.com/news/primary-care/20201208/this-was-a-gift-to-us-ivermectin-effective-for-covid19-prophylaxis-treatment. Accessed March 5, 2021.
Google Scholar46. Appelbaum, B . As U.S. agencies put more value on a life, businesses fret. The New York Times, February16, 2011.
Google Scholar47. Johns Hopkins University & Medicine . COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available from: https://coronavirus.jhu.edu/map.html. Accessed March 5, 2021.
Google Scholar48. worldometer . Current world population. Available from: https://www.worldometers.info/world-population/. Accessed March 5, 2021.
Google Scholar49. World Health Organization . Global price reporting mechanism for HIV, tuberculosis and malaria. 2020. Available from: https://www.who.int/hiv/amds/gprm/en/
Google Scholar50. World Bank . New country classifications by income level: 2019-2020. 2019. Available from: http://blogs.worldbank.org/opendata/new-country-classifications-income-level-2019-2020
Google Scholar51. Médecins Sans Frontières . Access to medicines: medicines shouldn’t be a luxury. 2020. Available from: https://www.msf.org/access-medicines-depth
Google Scholar52. Clinton Health Access Initiative . Annual report. 2018. Available from: http://clintonhealthaccess.org/wp-content/uploads/2019/12/CHAI-ANNUAL-REPORT.pdf
Google Scholar53. Desrosiers RC . HIV/AIDS vaccine: why don’t we have one after 37 years, when we have several for Covid-19 after a few months? The Conversation. May 17, 2021. Available from: https://theconversation.com/hiv-aids-vaccine-why-dont-we-have-one-after-37-years-when-we-have-several-for-covid-19-after-a-few-months-160690
Google Scholar54. Simon, HA . A behavioral model of rational choice. Q J Econ. 1955;69(1):99–118.
Google Scholar | Crossref | ISI55. Kahneman, D, Tversky, A. Prospect theory: an analysis of decision under risk. Econometrica. 1979;47(2):263–91.
Google Scholar | Crossref | ISI56. Sun, J, He, W-T, Wang, L, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020;26(5):483–95.
Google Scholar | Crossref | Medline